Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Firy Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Firy Inc. trades at $8.04 (market cap $125.48M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 64.1× Firy Inc.'s market cap. Which is the better fit depends on your goals.
| BIO | FIRY | |
|---|---|---|
Market Cap | $8.04B | $125.48M |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $12.45 |
52-Week Low | $241.71 | $2.28 |
Enterprise Value | $7.85B | $69.16M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
FIRY trades at $8.44, down 1.17% on the day, with a bullish technical signal from moving averages despite recent price weakness. The company reported Q1 2026 revenue growth but continues to post significant losses, with a net income margin of -57.48%. Recent developments include a corporate rebrand from Skillz Inc. and a major legal victory, though cash flow remains negative.
The outlook remains challenging due to persistent unprofitability and negative cash flows, offset by potential from the rebrand and legal win. Risks include high burn rate and competitive pressures. Analyst sentiment is mixed with a hold-dominated consensus, suggesting cautious optimism pending sustained operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
